For further information, please contact:
Per Norlén, CEO
Telephone: + 46 46 286 42 80 (switchboard)
Rein Piir, VP Investor Relations
Telephone: +46 708 537292
Per-Olof Schrewelius, CFO
Telephone: +46 46 286 42 85
The information in the press release is such that Alligator Bioscience AB is required to disclose pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 16.00 CET on 22 March, 2017.
About Alligator Bioscience
Alligator is a biotechnology company that develops innovative immune activating antibody drugs for tumor-directed immunotherapy. The Company has a pipeline of lead clinical and preclinical product candidates: ADC-1013, ATOR-1015 and ATOR-1016 as well as various research candidates. In August 2015, ADC-1013 was out-licensed to Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for further development and commercialization. The Company’s shares are listed on Nasdaq Stockholm under the ticker “ATORX”. The Company is headquartered in Lund, Sweden, and has approximately 40 employees. For more information, please visit http://www.alligatorbioscience.com.